{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:52Z","timestamp":1790739472688,"version":"4.1.0"},"reference-count":123,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00388","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T04:48:36Z","timestamp":1585111716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models"],"prefix":"10.3389","volume":"10","author":[{"given":"Christophe","family":"Blanquart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Jaurand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell immunotherapy for mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5858\/arpa.2011-0215-RA","article-title":"Molecular changes in mesothelioma with an impact on prognosis and treatment","volume":"136","author":"Jean","year":"2012","journal-title":"Arch Pathol Lab Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1038\/onc.2013.351","article-title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma","volume":"33","author":"Tallet","year":"2014","journal-title":"Oncogene."},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.36.15_suppl.8564","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.21037\/tlcr.2017.06.06","article-title":"Targeting the epigenome in malignant pleural mesothelioma","volume":"6","author":"McLoughlin","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/ijms19041163","article-title":"Non-coding transcript heterogeneity in mesothelioma: insights from asbestos-exposed mice","volume":"19","author":"Felley-Bosco","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3978\/j.issn.2072-1439.2015.04.56","article-title":"MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets","volume":"7","author":"Reid","year":"2015","journal-title":"J Thorac Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/ijms19051297","article-title":"In silico and in vitro analyses of LncRNAs as potential regulators in the transition from the epithelioid to sarcomatoid histotype of malignant pleural mesothelioma (MPM)","volume":"19","author":"Singh","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/9781681081946116010017","article-title":"Biomolecular pathways and malignant pleural mesothelioma","volume-title":"Malignant Pleural Mesothelioma: Present Status and Future Directions","author":"Jaurand","year":"2016"},{"key":"B33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the international mesothelioma interest group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in Malignant Pleural Mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reynies","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1610322","DOI":"10.1080\/23723556.2019.1610322","article-title":"Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach","volume":"6","author":"Blum","year":"2019","journal-title":"Mol Cell Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine."},{"key":"B41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J Transl Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/carcin\/bgz066","article-title":"Whole-genome sequencing of human malignant mesothelioma tumours and cell lines","volume":"40","author":"Oey","year":"2019","journal-title":"Carcinogenesis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in immune cell content in malignant pleural mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology."},{"key":"B46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrc.2017.69","article-title":"Classifying the evolutionary and ecological features of neoplasms","volume":"17","author":"Maley","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/cgt.2013.1","article-title":"Gene therapy for malignant mesothelioma: current prospects and challenges","volume":"20","author":"Tagawa","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3892\/ijo.2016.3367","article-title":"Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model","volume":"48","author":"Abu Lila","year":"2016","journal-title":"Int J Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2012.01873.x","article-title":"Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma","volume":"166","author":"Favoni","year":"2012","journal-title":"Br J Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br J Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.lungcan.2004.04.021","article-title":"The role of alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials","volume":"45","author":"Hanauske","year":"2004","journal-title":"Lung Cancer."},{"key":"B53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ijc.27611","article-title":"SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma","volume":"132","author":"Iwahori","year":"2013","journal-title":"Int J Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/1389450116666141205160924","article-title":"Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells","volume":"15","author":"Leon","year":"2014","journal-title":"Curr Drug Targets."},{"key":"B55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.18926\/AMO\/52140","article-title":"Preclinical evaluation of microRNA-34b\/c delivery for malignant pleural mesothelioma","volume":"68","author":"Ueno","year":"2014","journal-title":"Acta Med Okayama."},{"key":"B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2015.10.019","article-title":"Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed","volume":"220","author":"Ando","year":"2015","journal-title":"J Control Release."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/ejcts\/ezu393","article-title":"Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesotheliomadagger","volume":"47","author":"Meerang","year":"2015","journal-title":"Eur J Cardiothorac Surg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lungcan.2012.01.009","article-title":"Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer","volume":"77","author":"Iochmann","year":"2012","journal-title":"Lung Cancer."},{"key":"B59","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1148\/radiol.12121021","article-title":"Orthotopic pleural mesothelioma in mice: SPECT\/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies","volume":"267","author":"Nayak","year":"2013","journal-title":"Radiology."},{"key":"B60","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0046-8177(82)80083-X","article-title":"Studies of a human mesothelioma","volume":"13","author":"Behbehani","year":"1982","journal-title":"Hum Pathol."},{"key":"B61","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model","volume":"47","author":"Reale","year":"1987","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am J Pathol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ajpath.2010.10.039","article-title":"Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma","volume":"178","author":"Jean","year":"2011","journal-title":"Am J Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2018.10.015","article-title":"Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma","volume":"126","author":"Tranchant","year":"2018","journal-title":"Lung Cancer."},{"key":"B65","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ijc.2910550331","article-title":"In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines","volume":"55","author":"Zeng","year":"1993","journal-title":"Int J Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0046-8177(94)90192-9","article-title":"Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies","volume":"25","author":"Zeng","year":"1994","journal-title":"Hum Pathol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/cdd.2015.165","article-title":"Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease","volume":"23","author":"Chernova","year":"2016","journal-title":"Cell Death Differ."},{"key":"B68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-018-0891-0","article-title":"Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis","volume":"17","author":"Smeele","year":"2018","journal-title":"Mol Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/ijms19082191","article-title":"Mesotheliomas in Genetically engineered mice unravel mechanism of mesothelial carcinogenesis","volume":"19","author":"Jean","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","article-title":"Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery","volume":"87","author":"Ruggeri","year":"2014","journal-title":"Biochem Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/0008-5472.CAN-11-2786","article-title":"Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes","volume":"72","author":"Singh","year":"2012","journal-title":"Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials."},{"key":"B76","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.1158\/1078-0432.CCR-19-1836","article-title":"Nivo-lution in mesothelioma","volume":"25","author":"Mansfield","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B77","first-page":"426","article-title":"Acute injury and regeneration of the mesothelium in response to asbestos fibers","volume":"128","author":"Moalli","year":"1987","journal-title":"Am J Pathol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a murine model of malignant mesothelioma","volume":"52","author":"Davis","year":"1992","journal-title":"Int J Cancer."},{"key":"B80","first-page":"448","article-title":"Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats","volume":"129","author":"Craighead","year":"1987","journal-title":"Am J Pathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"34664","DOI":"10.18632\/oncotarget.8970","article-title":"Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine","volume":"7","author":"Roulois","year":"2016","journal-title":"Oncotarget."},{"key":"B82","doi-asserted-by":"publisher","first-page":"16311","DOI":"10.18632\/oncotarget.24632","article-title":"Characterization of increasing stages of invasiveness identifies stromal\/cancer cell crosstalk in rat models of mesothelioma","volume":"9","author":"Nader","year":"2018","journal-title":"Oncotarget."},{"key":"B83","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.lungcan.2010.12.020","article-title":"Bioluminescence imaging for in vivo monitoring of local recurrence mesothelioma model","volume":"71","author":"Shi","year":"2011","journal-title":"Lung Cancer."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00109-018-1725-7","article-title":"The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma","volume":"97","author":"Laszlo","year":"2019","journal-title":"J Mol Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13046-019-1352-3","article-title":"Dropwort-induced metabolic reprogramming restrains YAP\/TAZ\/TEAD oncogenic axis in mesothelioma","volume":"38","author":"Pulito","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/cas.12985","article-title":"Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model","volume":"107","author":"Abe","year":"2016","journal-title":"Cancer Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/cas.13580","article-title":"Podoplanin: an emerging cancer biomarker and therapeutic target","volume":"109","author":"Krishnan","year":"2018","journal-title":"Cancer Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-14-0487-T","article-title":"An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models","volume":"13","author":"Scales","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1038\/srep09928","article-title":"New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The generation and application of patient-derived xenograft model for cancer research","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat."},{"key":"B96","first-page":"181","article-title":"Transplantation of human malignant mesothelioma into nude mice","volume":"40","author":"Chahinian","year":"1980","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/1074-7613(95)90047-0","article-title":"Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain","volume":"2","author":"Cao","year":"1995","journal-title":"Immunity."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","article-title":"Spherical cancer models in tumor biology","volume":"17","author":"Weiswald","year":"2015","journal-title":"Neoplasia."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e39556","DOI":"10.1371\/journal.pone.0039556","article-title":"Changes in global gene expression associated with 3D structure of tumors: an ex vivo matrix-free mesothelioma spheroid model","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS ONE."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0150044","DOI":"10.1371\/journal.pone.0150044","article-title":"Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma","volume":"11","author":"Barbone","year":"2016","journal-title":"PLoS ONE."},{"key":"B102","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.1074\/jbc.M709698200","article-title":"Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids","volume":"283","author":"Barbone","year":"2008","journal-title":"J Biol Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e52753","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of noxa expression","volume":"7","author":"Barbone","year":"2012","journal-title":"PLoS ONE."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/cdd.2009.32","article-title":"Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates","volume":"16","author":"Daubriac","year":"2009","journal-title":"Cell Death Differ."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.21873\/anticanres.13530","article-title":"2-Deoxy-glucose enhances the effect of cisplatin and pemetrexed in reducing malignant pleural mesothelioma cell proliferation but not spheroid growth","volume":"39","author":"Gerogianni","year":"2019","journal-title":"Anticancer Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jtcvs.2015.02.020","article-title":"Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids","volume":"149","author":"Lei","year":"2015","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B107","doi-asserted-by":"publisher","first-page":"14242","DOI":"10.1021\/acsami.7b01737","article-title":"PEGylated anionic magnetofluorescent nanoassemblies: impact of their interface structure on magnetic resonance imaging contrast and cellular uptake","volume":"9","author":"Linot","year":"2017","journal-title":"ACS Appl Mater Interfaces."},{"key":"B108","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/jca.2.507","article-title":"Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy","volume":"2","author":"Phung","year":"2011","journal-title":"J Cancer."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e14640","DOI":"10.1371\/journal.pone.0014640","article-title":"The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy","volume":"6","author":"Xiang","year":"2011","journal-title":"PLoS ONE."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1038\/cddis.2011.58","article-title":"The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance","volume":"2","author":"Barbone","year":"2011","journal-title":"Cell Death Dis."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e1757","DOI":"10.1038\/cddis.2015.124","article-title":"Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K\/mTOR inhibitors","volume":"6","author":"Echeverry","year":"2015","journal-title":"Cell Death Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1080\/15548627.2016.1173799","article-title":"Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome","volume":"12","author":"Follo","year":"2016","journal-title":"Autophagy."},{"key":"B113","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","article-title":"A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance","volume":"33","author":"Kim","year":"2005","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e0182039","DOI":"10.1371\/journal.pone.0182039","article-title":"Pancreatic cancer cell\/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model","volume":"12","author":"Kuen","year":"2017","journal-title":"PLoS ONE."},{"key":"B115","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.actbio.2016.12.037","article-title":"Mimicking the tumor microenvironment to regulate macrophage phenotype and assessing chemotherapeutic efficacy in embedded cancer cell\/macrophage spheroid models","volume":"50","author":"Tevis","year":"2017","journal-title":"Acta Biomater."},{"key":"B116","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biomaterials.2018.02.030","article-title":"3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment","volume":"163","author":"Rebelo","year":"2018","journal-title":"Biomaterials."},{"key":"B117","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09339","article-title":"Translating cancer research into targeted therapeutics","volume":"467","author":"de Bono","year":"2010","journal-title":"Nature."},{"key":"B118","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1517\/17460441.2013.768984","article-title":"How can attrition rates be reduced in cancer drug discovery?","volume":"8","author":"Moreno","year":"2013","journal-title":"Exp Opin Drug Discov."},{"key":"B119","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2015.03.040","article-title":"The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease","volume":"759","author":"Graham","year":"2015","journal-title":"Eur J Pharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s12885-018-4302-0","article-title":"In silico cancer research towards 3R","volume":"18","author":"Jean-Quartier","year":"2018","journal-title":"BMC Cancer."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e1801363","DOI":"10.1002\/adhm.201801363","article-title":"Organ-on-a-chip for cancer and immune organs modeling","volume":"8","author":"Sun","year":"2019","journal-title":"Adv Healthc Mater."},{"key":"B122","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: raise standards for preclinical cancer research","volume":"483","author":"Begley","year":"2012","journal-title":"Nature."},{"key":"B123","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/542025a","article-title":"Consider drug efficacy before first-in-human trials","volume":"542","author":"Kimmelman","year":"2017","journal-title":"Nature."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T04:48:54Z","timestamp":1585111734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":123,"alternative-id":["10.3389\/fonc.2020.00388"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00388","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"article-number":"388"}}